RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
- 4 October 2002
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 21 (45) , 6908-6914
- https://doi.org/10.1038/sj.onc.1205834
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 70 references indexed in Scilit:
- Third (fourth and fifth) nonocular tumors in survivors of retinoblastomaOphthalmology, 2001
- Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdksBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2001
- Pathways governing G1/S transition and their response to DNA damageFEBS Letters, 2001
- Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinomaExperimental and Clinical Endocrinology & Diabetes, 2000
- The p21Cip1 and p27Kip1 CDK `inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblastsThe EMBO Journal, 1999
- Ras Oncogene Mutations in Thyroid TumorsDiagnostic Molecular Pathology, 1996
- Rates of p16 ( MTS1 ) Mutations in Primary Tumors with 9p LossScience, 1994
- v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line.Journal of Clinical Investigation, 1990
- Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiationCell, 1989
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesPublished by Elsevier ,1988